Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV

04.02.2003


In a new study in mice, a modified form of an innocuous chimpanzee virus has shown marked potency as a protective vaccine against HIV, itself believed to have crossed into the human population from chimpanzees sometime in the 1930s. The study, led by researchers at The Wistar Institute, appears in the February issue of the Journal of Immunology.



"Our results show this new vaccine is capable of inducing the kind of powerful immune response that we and others believe will be critical for controlling HIV infection," says Hildegund C.J. Ertl, M.D., professor and immunology program leader at The Wistar Institute, and senior author on the new study.

Given the history of HIV, Ertl emphasize the lengths to which she and her colleagues have gone to ensure that the new vaccine is completely safe. To eliminate the possibility of any contaminant - an HIV-like stowaway, for example - the vaccine is derived in the laboratory from a set of genetic instructions. Importantly, too, the genes that would be needed by the viral vaccine to replicate are deleted from those instructions.


The vaccine is based on a chimpanzee adenovirus. In chimpanzees and humans, adenoviruses are a common cause of respiratory-tract infections. Immunologists have understood for some time that human adenoviruses can be retooled in the laboratory to serve as the basis for vaccines against an array of viral diseases. They easily enter human cells and stimulate a vigorous, long-lasting immune response. A number of vaccines based on human adenoviruses, including some against HIV, are now in development.

An unaddressed concern with these vaccines, however, is the question of pre-existing immunity. Adenoviruses are nearly ubiquitous among humans, so much so that more than 45 percent of the population has neutralizing antibodies circulating in the blood able to impair any vaccine based on a common human adenovirus. But the new chimpanzee adenovirus vaccine possesses the immunological strengths of a human adenovirus vaccine without the drawback of pre-existing immunity in its target population.

Because HIV infects only humans and chimpanzees, the current study used a sophisticated mouse model to test the new vaccine. For this model, the researchers first incorporated an internal HIV protein known as gag into the modified chimpanzee adenovirus vaccine. They also engineered a matching vaccine that incorporated gag into the human adenovirus. They then used a variant of the vaccinia virus, which can infect mice, that included the gag protein. For comparison, some mice were exposed to the human adenovirus, so that they would demonstrate the pre-existing immunity to the virus seen in many humans.

After vaccination with the chimpanzee adenovirus vaccine, the mice mounted a powerful T-cell-based immune response and were able to fight off experimental infection by the vaccinia virus containing gag, the HIV protein. The mice pre-exposed to the human adenovirus and vaccinated with the human adenovirus vaccine, however, demonstrated significantly weaker immune responses to the vaccinia virus.

"It’s hard to say that because the vaccine works well in a mouse model, it will protect humans from HIV infection," Ertl cautions. "But we do know that the kind of immune response we saw in mice can protect non-human primates infected with SIV from developing disease." SIV, or simian immunodeficiency virus, is the chimpanzee counterpart to HIV, or human immunodeficiency virus.

In addition to moving forward with testing of the chimpanzee adenovirus vaccine against HIV, Ertl and her colleagues are developing similar vaccines against rabies, smallpox, and a number of other viruses.

Julie C. Fitzgerald, a graduate student in senior author Ertl’s laboratory, is lead author on the Journal of Immunology study. The other Wistar-based authors are Zhi Q. Xiang, Anthony P. Wlazlo, and Wynetta Giles-Davis. Arturo Reyes-Sandoval is affiliated with Wistar and the Instituto Politecnico Nacional in Mexico City. George N. Pavlakis is with the National Cancer Institute. Guang-Ping Gao and James M. Wilson are with the University of Pennsylvania. The techniques used to create the vaccine were developed under the guidance of Wilson and his colleagues.


Funding for the research was provided by the National Institutes of Health, the W.W. Smith Foundation, and Genovo. Wilson owns equity in Targeted Genetics, formerly Genovo.

The Wistar Institute is an independent nonprofit biomedical research institution dedicated to discovering the causes and cures for major diseases, including cancer, cardiovascular disease, autoimmune disorders, and infectious diseases. Founded in 1892 as the first institution of its kind in the nation, The Wistar Institute today is a National Cancer Institute-designated Cancer Center - one of only eight focused on basic research. Discoveries at Wistar have led to the development of vaccines for such diseases as rabies and rubella, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.

Franklin Hoke | EurekAlert!
Further information:
http://www.wistar.upenn.edu

More articles from Health and Medicine:

nachricht How prenatal maternal infections may affect genetic factors in Autism spectrum disorder
22.03.2017 | University of California - San Diego

nachricht Camouflage apples
22.03.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Pulverizing electronic waste is green, clean -- and cold

22.03.2017 | Materials Sciences

Astronomers hazard a ride in a 'drifting carousel' to understand pulsating stars

22.03.2017 | Physics and Astronomy

New gel-like coating beefs up the performance of lithium-sulfur batteries

22.03.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>